Astellas Pharma Inc (OTCPK:ALPMY)
$ 9.68 -0.12 (-1.22%) Market Cap: 17.36 Bil Enterprise Value: 21.12 Bil PE Ratio: 0 PB Ratio: 1.81 GF Score: 77/100

Full Year 2019 Astellas Pharma Inc Earnings Call Transcript

Apr 25, 2019 / 05:00AM GMT
Release Date Price: $13.14 (-3.10%)
Kenji Yasukawa
Astellas Pharma Inc. - President, CEO & Director

Once again, good afternoon, ladies and gentlemen. I'm Yasukawa. Today, I'd like to present on the financial results for fiscal year 2019. Thank you very much for coming to our meeting today. So I would like explain first, and then we will entertain your questions later.

Next page please. This is a cautionary statement regarding forward-looking information. I'm not going to read the contents here. Page 3 is the agenda today. First, I will present on the consolidated financial results for fiscal year 2018, and also I will talk about the forecast for the current fiscal year, fiscal year 2019. And then I will talk about the (inaudible) forecast for 2019 and beyond, I will talk about initiatives for sustainable growth, and at the end, I will explain the capital allocation.

Next page please. First, financial result on a core basis. In FY 2018, revenues and profits increased, sales and revenues, revenues here are shown, revenues were JPY 1.3063 trillion, up 0.5% year-on-year. In the middle, you can find core operating profit,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot